LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

Crinetics Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

31.3 1.26

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

30.33

Максимум

31.56

Ключови измерители

By Trading Economics

Приходи

-16M

-97M

Продажби

361K

361K

EPS

-1.04

Марж на печалбата

-26,807.202

Служители

437

EBITDA

-6.9M

-94M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+151.05% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-41M

3.1B

Предишно отваряне

30.04

Предишно затваряне

31.3

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2025 г., 20:54 ч. UTC

Придобивния, сливания и поглъщания

PNC to Buy Private-Equity Agent Aqueduct Capital

20.05.2025 г., 20:50 ч. UTC

Печалби

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20.05.2025 г., 23:52 ч. UTC

Горещи акции

Stocks to Watch: Wolfspeed, Palo Alto Networks, QXO, Take-Two Interactive Software

20.05.2025 г., 23:48 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20.05.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20.05.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20.05.2025 г., 23:08 ч. UTC

Пазарно говорене

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20.05.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20.05.2025 г., 22:45 ч. UTC

Придобивния, сливания и поглъщания

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20.05.2025 г., 22:20 ч. UTC

Топ новини

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20.05.2025 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q Adj EPS 36c >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q EPS 10c >JHX

20.05.2025 г., 21:44 ч. UTC

Печалби

James Hardie Industries 4Q Sales $972M >JHX

20.05.2025 г., 20:52 ч. UTC

Топ новини

Elon Musk to Cut Back Political Spending -- 3rd Update

20.05.2025 г., 20:52 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2025 г., 20:52 ч. UTC

Пазарно говорене

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20.05.2025 г., 20:28 ч. UTC

Придобивния, сливания и поглъщания

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20.05.2025 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20.05.2025 г., 20:22 ч. UTC

Печалби

XP 1Q Adj EPS BRL2.29 >XP

20.05.2025 г., 20:22 ч. UTC

Печалби

XP 1Q Rev BRL4.345B >XP

20.05.2025 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20.05.2025 г., 20:20 ч. UTC

Топ новини

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20.05.2025 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20.05.2025 г., 20:11 ч. UTC

Топ новини

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20.05.2025 г., 20:09 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Сравнение с други в отрасъла

Ценова промяна

Crinetics Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

151.05% нагоре

12-месечна прогноза

Среден 77.7 USD  151.05%

Висок 100 USD

Нисък 53 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Crinetics Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

11

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

30.39 / 33.46Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Neutral Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.